[Edaily Reporter Shin Ha-yeon ] JEONJINBIO CO., LTD.(110020)announced on the 22nd that it is expanding the supply of its new home care product line to target the global market.
The company recently finalized a deal to supply new home care products to a global distribution firm with annual revenue of 2 trillion won on a consolidated basis, both domestically and internationally. These products, which form a new home care line following the company’s existing flagship item—capsule detergent—are scheduled to be supplied to domestic and international distribution networks after passing quality verification by the global client. A view of JEONJINBIO CO., LTD.’s headquarters. (Photo: JEONJINBIO CO., LTD.) JEONJINBIO CO., LTD. plans to use this supply agreement as an opportunity to increase the proportion of overseas sales in its home care business and strengthen cooperation with global partners. The company intends to leverage its partners’ global distribution networks to increase market share while simultaneously pursuing revenue growth and improved profitability in this business segment.
JEONJINBIO CO., LTD. official stated, “Following our existing capsule detergents, our new home care products also meet the strict standards of our global partners, allowing us to expand our supply contracts,” adding, “Based on our sales network and technological capabilities, we will continuously increase overseas supply volumes to cultivate the home care business as a core growth engine.”
Global digital marketing specialist Wise birds Inc.(273060)is accelerating its expansion into the cross-border e-commerce market. Targeting the rapidly growing TikTok Shop ecosystem, the company has u…
HYUNDAILIVART, which is targeting the office furniture market, has received recognition for its designs developed to reduce physical strain even in environments with long working hours.
The FITTER …
DB Securities assessed that the prospects for a global technology export have increased for “Isuzinaxib” (APX115), a kidney disease treatment developed by Aptabio Therapeutics Inc.(293780), after it d…